Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Integrated Phase II/III, Open Label, Randomized and Controlled Study of the Safety and Efficacy of CG0070 Adenovirus Vector Expressing GM-CSF in Patients With NMIBC With Carcinoma In Situ Disease Who Have Failed BCG

Next Previous
X
Search
Trial Profile

An Integrated Phase II/III, Open Label, Randomized and Controlled Study of the Safety and Efficacy of CG0070 Adenovirus Vector Expressing GM-CSF in Patients With NMIBC With Carcinoma In Situ Disease Who Have Failed BCG

Status: Discontinued
Phase of Trial: Phase II/III

Latest Information Update: 07 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cretostimogene grenadenorepvec (Primary) ; Gemcitabine; Interferon; Mitomycin; Valrubicin
  • Indications Bladder cancer; Carcinoma; Urogenital cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms BOND
  • Sponsors CG Oncolgy

    • Most Recent Events

    • 25 Mar 2020 According to a Cold Genesys media release, Cold Genesys changed its name to CG Oncology
    • 27 Jul 2016 Status changed from active, no longer recruiting to discontinued. Reason the study was stopped is Change in study design.
    • 10 May 2016 Results of subgroup analysis (n=22) presented at the 111th Annual Meeting of the American Urological Association

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top